Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum Adjuvant, and Co-administered With a Licensed Inactivated Influenza Vaccine, in Healthy Subjects ≥ 60 Years of Age.

NCT01709019 is registered in ClinicalTrials.gov with Novavax as lead sponsor.

NCT NCT01709019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01709019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum Adjuvant, and Co-administered With a Licensed Inactivated Influenza Vaccine, in Healthy Subjects ≥ 60 Years of Age.
Lead sponsor
Novavax
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2012
Completion date
March 31, 2014
Enrollment
220 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)